Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus.

Micić D, Macut D, Popović V, Kendereski A, Sumarac-Dumanović M, Zorić S, Dieguez C, Casanueva FF

Metabolism: clinical and experimental1 Apr 1999Cited by 12 (Europe PMC)

PMID10206449DOI10.1016/s0026-0495(99)90115-4PepBankPUB-10206449

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In patients with NIDDM and controls, the peak GH response to GHRP‑6 did not differ between normal-weight patients, overweight patients and controls.
In plain wordsIn adults with type 2 diabetes and in controls, GHRP‑6 raised growth hormone peaks to a similar level in all three groups.
Peptide
GHRP-6
Outcome
No significant changePeak GH after GHRP-6
Study
n = 29
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
90 microg · intravenousAs given in this study (human).
Source sentences
Summary
There was no difference between the GH response after GHRP-6 in groups A, B, and C in terms of the GH peak (50.95+/-11.55, 51.96+/-7.71, and 70.07+/-15.59 mU/L, P>.05) and the area under the curve (AUC) for GH (2,340.06+/-617.36, 2,684.54+/-560.57, 3,462.78+/-1,223.53 mU/L/120 min, P>.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
Report a problemFND-1020644901
02HumanNon-randomized trialEfficacy outcome
In patients with NIDDM and controls, the GH area under the curve after GHRP‑6 did not differ between normal-weight patients, overweight patients and controls.
In plain wordsIn adults with type 2 diabetes and in controls, the total growth hormone release after GHRP‑6 was similar in all three groups.
Peptide
GHRP-6
Outcome
No significant changeGH area under the curve after GHRP-6
Study
n = 29
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
90 microg · intravenousAs given in this study (human).
Source sentences
Summary
There was no difference between the GH response after GHRP-6 in groups A, B, and C in terms of the GH peak (50.95+/-11.55, 51.96+/-7.71, and 70.07+/-15.59 mU/L, P>.05) and the area under the curve (AUC) for GH (2,340.06+/-617.36, 2,684.54+/-560.57, 3,462.78+/-1,223.53 mU/L/120 min, P>.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
Report a problemFND-1020644902

Studies that did not test the peptide alone7

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

03HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
In patients with NIDDM and controls, combined GHRP‑6 plus GHRH gave a synergistic GH response.
In plain wordsIn adults with type 2 diabetes and in controls, GHRP‑6 given together with GHRH gave a stronger growth hormone response than expected from each alone.
Peptide
GHRP-6
Outcome
IncreaseGH response to GHRP-6 plus GHRH in NIDDM patients and controls
Study
n = 29
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The combined administration of GHRP-6 + GHRH elicited a synergistic GH response in NIDDM patients and controls.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644903
04HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the peak GH was lower in overweight NIDDM patients than in normal-weight NIDDM patients.
In plain wordsAfter GHRP‑6 with GHRH, overweight adults with type 2 diabetes had a lower growth hormone peak than normal-weight adults with type 2 diabetes.
Peptide
GHRP-6
Outcome
DecreasePeak GH after GHRP-6 plus GHRH, overweight versus normal-weight NIDDM
Study
n = 21
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was a significant difference between groups A and B for the GH peak (96.49+/-9.80 v 68.38+/-8.25, P<.05), whereas there was no difference for the AUC (5,111.13+/-703.77 v 3,425.95+/-459.67, P>.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644904
05HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the GH area under the curve did not differ between overweight and normal-weight NIDDM patients.
In plain wordsAfter GHRP‑6 with GHRH, total growth hormone release was similar in overweight and normal-weight adults with type 2 diabetes.
Peptide
GHRP-6
Outcome
No significant changeGH area under the curve after GHRP-6 plus GHRH, overweight versus normal-weight NIDDM
Study
n = 21
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was a significant difference between groups A and B for the GH peak (96.49+/-9.80 v 68.38+/-8.25, P<.05), whereas there was no difference for the AUC (5,111.13+/-703.77 v 3,425.95+/-459.67, P>.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644905
06HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the peak GH did not differ between normal-weight NIDDM patients and controls.
In plain wordsAfter GHRP‑6 with GHRH, normal-weight adults with type 2 diabetes and controls had a similar growth hormone peak.
Peptide
GHRP-6
Outcome
No significant changePeak GH after GHRP-6 plus GHRH, normal-weight NIDDM versus controls
Study
n: not reported in source
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no difference in the peak GH after the combined test between group A and group C (96.49+/-9.80 v 139.82+/-24.16, P>.05), whereas the peak GH in the same test was significantly decreased in group B in comparison to group C (68.38+/-8.25 v 139.82+/-24.16, P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644906
07HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the peak GH was lower in overweight NIDDM patients than in controls.
In plain wordsAfter GHRP‑6 with GHRH, overweight adults with type 2 diabetes had a lower growth hormone peak than controls.
Peptide
GHRP-6
Outcome
DecreasePeak GH after GHRP-6 plus GHRH, overweight NIDDM versus controls
Study
n: not reported in source
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no difference in the peak GH after the combined test between group A and group C (96.49+/-9.80 v 139.82+/-24.16, P>.05), whereas the peak GH in the same test was significantly decreased in group B in comparison to group C (68.38+/-8.25 v 139.82+/-24.16, P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644907
08HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the GH area under the curve did not differ between normal-weight NIDDM patients and controls.
In plain wordsAfter GHRP‑6 with GHRH, total growth hormone release was similar in normal-weight adults with type 2 diabetes and controls.
Peptide
GHRP-6
Outcome
No significant changeGH area under the curve after GHRP-6 plus GHRH, normal-weight NIDDM versus controls
Study
n: not reported in source
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The AUC for GH after combined GHRP-6 + GHRH in group A versus group C was not significantly different (5,111.13+/-703.77 v 9,274.71+/-1,541.46, P>.05), whereas there was a significant difference for the same test between group B and group C (3,425.95+/-459.67 v 9,274.71+/-1,541.46, P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644908
09HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome
After combined GHRP‑6 plus GHRH, the GH area under the curve was lower in overweight NIDDM patients than in controls.
In plain wordsAfter GHRP‑6 with GHRH, overweight adults with type 2 diabetes had lower total growth hormone release than controls.
Peptide
GHRP-6
Outcome
DecreaseGH area under the curve after GHRP-6 plus GHRH, overweight NIDDM versus controls
Study
n: not reported in source
Comparator
Normal-weight control subjects
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
The AUC for GH after combined GHRP-6 + GHRH in group A versus group C was not significantly different (5,111.13+/-703.77 v 9,274.71+/-1,541.46, P>.05), whereas there was a significant difference for the same test between group B and group C (3,425.95+/-459.67 v 9,274.71+/-1,541.46, P<.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty-one patients with NIDDM were divided into two groups: group A, normal weight (body mass index [BMI], 23.31+/-0.62 kg/m2); and group B, overweight (BMI, 27.62+/-0.72 kg/m2).
Summary · context
Each subject received GHRP-6 (90 microg intravenously [i.v.]), GHRH (100 microg i.v.), and GHRP-6 + GHRH on three separate occasions.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-1020644909

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.